Last updated on November 2016

LixiLan-G EFC13794

Brief description of study

LixiLan-G EFC13794

Detailed Study Description

A 26-week open-label study assessing the efficacy and safety of the insulin glargine/lixisenatide fixed ratio combination in adults with Type 2 Diabetes inadequately controlled on GLP-1 receptor agonist and metformin ± pioglitazone.

Clinical Study Identifier: TX146000

Find a site near you

Start Over

Diabetes Associates Medical Group / Clinical Research

1234 W. Chapman Ave., Suite 106 Orange, CA USA
  Connect »